Phase I/II trial of gefitinib and RAD001 (everolimus) in patients (pts) with advanced non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Milton, DT [1 ]
Kris, MG [1 ]
Azzoli, CG [1 ]
Gomez, JE [1 ]
Heelan, R [1 ]
Krug, LM [1 ]
Pao, W [1 ]
Pizzo, B [1 ]
Rizvi, NA [1 ]
Miller, VA [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：646S / 646S
页数：1
相关论文
共 50 条
  • [31] Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC)
    Bearz, Alessandra
    Fratino, Lucia
    Spazzapan, Simon
    Berretta, Massimiliano
    Giacalone, Annalisa
    Simonelli, Cecilia
    Tirelli, Umberto
    LUNG CANCER, 2007, 55 (01) : 125 - 127
  • [32] Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC):: a phase I trial
    Krajnik, G
    Wein, W
    Greil, R
    Marhold, F
    Mohn-Staudner, A
    Kummer, F
    Malayeri, R
    Zöchbauer-Müller, S
    Huber, H
    Pirker, R
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (12) : 1977 - 1980
  • [33] Safety and efficacy of gefitinib monotherapy for patients (pts) ≥80 years (yrs) with advanced non-small cell lung cancer (NSCLC): A phase II subset analysis
    Ebi, N.
    Semba, H.
    Tokunaga, S.
    Takayama, K.
    Wataya, H.
    Kuraki, T.
    Yamamoto, H.
    Akamine, S.
    Okamoto, I.
    Nakanishi, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Soria, J. C.
    Bennouna, J.
    Leighl, N.
    Khuri, F.
    Traynor, A. M.
    Johnson, B.
    Kay, A.
    Blais, N.
    Jehl, V.
    Papadimitrakopoulou, V.
    EJC SUPPLEMENTS, 2009, 7 (02): : 558 - 559
  • [35] Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC)
    Leighl, N. B.
    Soria, J.
    Bennouna, J.
    Blais, N.
    Traynor, A. M.
    Papadimitrakopoulou, V.
    Klimovsky, J.
    Jappe, A.
    Jehl, V.
    Johnson, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [36] Phase I trial of RAD001 (everolimus) plus sunitinib in patients with metastatic renal cell carcinoma
    Kroog, G. S.
    Feldman, D. R.
    Kondagunta, G. V.
    Ginsberg, M. S.
    Fischer, P. M.
    Trinos, M. J.
    Patil, S.
    Ishill, N. M.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [37] Phase I/II trial of combination nab-paclitaxel and pemetrexed in advanced solid tumor patients (pts) with emphasis on non-small cell lung cancer (NSCLC).
    Riess, Jonathan
    Ho, Cheryl
    Davies, Angela M.
    Lau, Derick
    Lara, Primo
    Chew, Helen K.
    Beckett, Laurel
    Sangha, Randeep S.
    Mack, Philip C.
    Gandara, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Update of the oxaliplatin (L-OHP)/navelbine (NVB) phase I/II multicentric trial in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    De Cremoux, H
    Bekradda, M
    Monnet, I
    Soulie, P
    Saltiel, S
    Misset, JL
    Fandi, A
    Bensmaine, MA
    Cvitkovic, E
    ANNALS OF ONCOLOGY, 1998, 9 : 98 - 98
  • [39] Phase I/II trial of bortezimib and pemetrexed in patients with advanced non-small cell lung cancer
    Natale, R. B.
    McKinley, M.
    Hilger, J.
    Myers, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Phase I/II study of gefitinib in combination with vorinostat in patients with advanced non-small cell lung cancer (NSCLC) who progressed on prior chemotherapy
    Han, Ji-Youn
    Lee, Soo Hyun
    Yun, Tak
    Lee, Young Jooo
    Hwang, Kum Hui
    Ryu, Sunah
    Kim, Heung Tae
    Lee, Jin Soo
    CANCER RESEARCH, 2014, 74 (19)
12345